Literature DB >> 1720753

Construction of plasmid vectors with a non-antibiotic selection system based on the Escherichia coli thyA+ gene: application to cholera vaccine development.

R Morona1, J Yeadon, A Considine, J K Morona, P A Manning.   

Abstract

The construction of live oral carriers based on attenuated Salmonella strains as vectors offers a new approach to vaccine development. We have constructed a set of plasmid vectors which have the thyA gene of Escherichia coli (encoding thymidylate synthetase) as the marker for selection and maintenance of plasmid clones. The thyA system offers an alternative to antibiotic-resistance selection markers. It can be easily adapted to a particular host-vector combination since thyA chromosomal mutations can be readily introduced by trimethoprim selection. We also describe the construction of thyA-based plasmids with the Vibrio cholerae rfb genes (encoding O-antigen biosynthesis of the Inaba serotype). These have been found to be useful in the construction of candidate bivalent cholera-typhoid vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720753     DOI: 10.1016/0378-1119(91)90307-w

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  10 in total

1.  Genetic transformation of Veillonella parvula.

Authors:  Jinman Liu; Justin Merritt; Fengxia Qi
Journal:  FEMS Microbiol Lett       Date:  2011-07-18       Impact factor: 2.742

Review 2.  Salmonella as a vaccine delivery vehicle.

Authors:  Kenneth L Roland; Karen E Brenneman
Journal:  Expert Rev Vaccines       Date:  2013-09       Impact factor: 5.217

3.  Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathway.

Authors:  Wei-Ren Dong; Li-Xin Xiang; Jian-Zhong Shao
Journal:  Appl Environ Microbiol       Date:  2010-01-29       Impact factor: 4.792

4.  A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection.

Authors:  James E Galen; Jin Yuan Wang; Jose A Carrasco; Scott A Lloyd; Gabriela Mellado-Sanchez; Jovita Diaz-McNair; Olga Franco; Amanda D Buskirk; James P Nataro; Marcela F Pasetti
Journal:  Infect Immun       Date:  2014-10-20       Impact factor: 3.441

5.  Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium.

Authors:  Helen S Garmory; Matthew W Leckenby; Kate F Griffin; Stephen J Elvin; Rosa R Taylor; M Gill Hartley; Julian A J Hanak; E Diane Williamson; Rocky M Cranenburgh
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

6.  In-Depth Characterization of a Re-Engineered Cholera Toxin Manufacturing Process Using Growth-Decoupled Production in Escherichia coli.

Authors:  Natalia Danielewicz; Wenyue Dai; Francesca Rosato; Michael E Webb; Gerald Striedner; Winfried Römer; W Bruce Turnbull; Juergen Mairhofer
Journal:  Toxins (Basel)       Date:  2022-06-08       Impact factor: 5.075

7.  Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains.

Authors:  Konstantin Rizos; Claus T Lattemann; Dirk Bumann; Thomas F Meyer; Toni Aebischer
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine strains.

Authors:  Uwe Kramer; Konstantin Rizos; Heiko Apfel; Ingo B Autenrieth; Claus T Lattemann
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

9.  Live bacterial vaccines--a review and identification of potential hazards.

Authors:  Ann Detmer; Jacob Glenting
Journal:  Microb Cell Fact       Date:  2006-06-23       Impact factor: 5.328

10.  A Novel Nonantibiotic, lgt-Based Selection System for Stable Maintenance of Expression Vectors in Escherichia coli and Vibrio cholerae.

Authors:  Manuela Terrinoni; Stefan L Nordqvist; Susanne Källgård; Jan Holmgren; Michael Lebens
Journal:  Appl Environ Microbiol       Date:  2018-01-31       Impact factor: 4.792

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.